cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
INDONESIAN JOURNAL OF PHARMACY
ISSN : 23389427     EISSN : 23389486     DOI : -
Core Subject : Health,
Indonesian Journal of Pharmacy (ISSN-e: 2338-9486, ISSN-p: 2338-9427), formerly Majalah Farmasi Indonesia (ISSN: 0126-1037). The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education (DGHE) DIKTI No. 58/DIKTI/Kep/2013.
Arjuna Subject : -
Articles 2 Documents
Search results for , issue " Vol 23 No 2, 2012" : 2 Documents clear
THE OPTIMISED CONDITIONS OF INDUCTION OF RECOMBINANT RIP rMJC15310 ACTIVITY ISOLATED FROM Mirabilis jalapa L. LEAVES Astuti, Puji; ., Sudjadi; ., Sismindari
INDONESIAN JOURNAL OF PHARMACY Vol 23 No 2, 2012
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (836.5 KB) | DOI: 10.14499/indonesianjpharm0iss0pp93-98

Abstract

Ribosome Inactivating Proteins (RIPs) are compounds isolated from plants with ability to inhibit protein synthesis. The inhibition of protein synthesis is due to inactivation of ribosomal RNA through a site-specific  deadenylation  mediated  by  RNA  N-glycosidase. Reportedly, RIPs mainly possess wide range of bioactivity including antiviral  activity  against  plant  infections.  Other  activities  of  RIP were  as  abortifacien,  antivirus  and  anticancer.  This  study  was aimed  to  isolate  and  characterize  the  optimum  conditions  for inducing  the  expression  of  recombinant  RIPs  isolated  from  the leaves  of  Mirabilis  Jalapa  L.  We  have  been  successfully  isolated several  RIPs  and  engineered  these  proteins  to  be  expressed  in  E. coli. These recombinant proteins were obtained by screening cDNA library  originated  from  the  mRNA  of  Mirabilis  jalapa  L  leaves,  and inserted  into  pUC19  carrying  lacZ  gene.  The  presence  of recombinant  plasmid  was  tested  by  using  α-complementation assay. Many RIPs have been isolated from plants and these proteins express  enzymatic  activity  by  cutting  supercoiled  double  stranded DNA. One RIP namely rMJC15310 was obtained from this study and the  proteins  having  ~  8kb  in  size,  cut  the  supercoiled  DNA  into linear  form  at  the  concentration  as  low  as  5  µg.  The  ability  to  cut supercoiled  DNA  increased  on  inducing  its  expression  with  0.4% IPTG.Key words:   Ribosome  Inactivating  Proteins  (RIP),  IPTG,  Mirabilis  jalapa L., recombinant protein 
IDENTIFICATION OF SAFETY ALERT BY MONITORING ANALYTICAL PARAMETERS AND HIGH-RISK DRUGS Vilaplana, Vicente Escudero-; Antúnez, María Gómez-; García, Esther Durán-; Míguez, Antonio Muiño-; Sáez, María Sanjurjo-
INDONESIAN JOURNAL OF PHARMACY Vol 23 No 2, 2012
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (662.163 KB) | DOI: 10.14499/indonesianjpharm0iss0pp130-134

Abstract

Early detection of  adverse  drug  reactions  (ADR) increases patient  safety.  Our  objective  was  to  identify  ADR  by  monitoring laboratory  parameters  and  high-risk  drugs.  We  carried  out  a two-month  prospective  observational  study  in  a  Internal Medicine  Department,  with  daily  recording  of  drugs  prescribed and  the  following  parameters:  Na,  K,  Ca,  serum  creatinine, glomerular  filtration  rate  (GFR),  INR,  glucose,  haemoglobin, platelets,  ALT,  AST,  bilirubin,  GGT,  alkaline  phosphatase,  TSH, T4,  and  blood  digoxin.  High-risk  drugs  were  closely  monitored. 52  patients  included,  of  whom  46.2%  experienced  an  ADR.  We observed  an  association  with  drugs  in  25.5%,  as  follows: reduction  in  GFR,  26.9%  (associated  with  loop  diuretics [41.7%],  angiotensin-converting  enzyme  [ACE]  inhibitors [33.3%],  angiotensin  II  receptor  blockers  [ARB]  [16.6%],  andanti-diabetic  drugs  [8.3%]);  hypokalemia,  22.3%  (associated with  loop  diuretics  [50.0%],  potassium-free  fluid  [37.5%],  and salbutamol  [12.5%]);  hyperkalemia,  14.4%  (associated  with ACE  inhibitors  [60.0%]  and  ARB  [40.0%]);  INR  out  of  range, 10.8%  (associated  with  drug  interactions  [66.7%]); hyperglycemia,  8.1%  (associated  with  corticosteroids  [66.7%] and  anti-diabetic  drugs  [33.3%]);  and  other  conditions,  18.8%. We  conclued  that  patient  safety  could  be  improved  by implementing  warnings  in  electronic  prescriptions  in  cases  of  a decrease  in  GFR  or  modification  of  potassium  levels  in  patients who are prescribed loop diuretics, ACE inhibitors, or ARBs.Key words:   Adverse drug reaction,  clinical decision support,  high-risk drug, safety 

Page 1 of 1 | Total Record : 2


Filter by Year

2012 2012


Filter By Issues
All Issue Vol 31 No 2, 2020 Vol 31 No 1, 2020 In Press Vol 31 No 1, 2020 Vol 30 No 4, 2019 Vol 30 No 3, 2019 Vol 30 No 2, 2019 Vol 30 No 2, 2019 Vol 30 No 1, 2019 Vol 30 No 1, 2019 Vol 29 No 4, 2018 Vol 29 No 4, 2018 Vol 29 No 3, 2018 Vol 29 No 3, 2018 Vol 29 No 2, 2018 Vol 29 No 1, 2018 Vol 28 No 4, 2017 Vol 28 No 4, 2017 Vol 28 No 3, 2017 Vol 28 No 3, 2017 Vol 28 No 2, 2017 Vol 28 No 2, 2017 Vol 28 No 1, 2017 Vol 27 No 4, 2016 Vol 27 No 4, 2016 Vol 27 No 3, 2016 Vol 27 No 3, 2016 Vol 27 No 2, 2016 Vol 27 No 2, 2016 Vol 27 No 1, 2016 Vol 27 No 1, 2016 Vol 26 No 4, 2015 Vol 26 No 4, 2015 Vol 26 No 3, 2015 Vol 26 No 3, 2015 Vol 26 No 2, 2015 Vol 26 No 1, 2015 Vol 26 No 1, 2015 Vol 25 No 4, 2014 Vol 25 No 4, 2014 Vol 25 No 3, 2014 Vol 25 No 3, 2014 Vol 25 No 2, 2014 Vol 25 No 1, 2014 Vol 25 No 1, 2014 Vol 24 No 4, 2013 Vol 24 No 4, 2013 Vol 24 No 3, 2013 Vol 24 No 3, 2013 Vol 24 No 2, 2013 Vol 24 No 2, 2013 Vol 24 No 1, 2013 Vol 24 No 1, 2013 Vol 23 No 4, 2012 Vol 23 No 3, 2012 Vol 23 No 2, 2012 Vol 23 No 2, 2012 Vol 23 No 1, 2012 Vol 23 No 1, 2012 Vol 22 No 4, 2011 Vol 22 No 4, 2011 Vol 22 No 3, 2011 Vol 22 No 3, 2011 Vol 22 No 2, 2011 Vol 22 No 2, 2011 Vol 22 No 1, 2011 Vol 21 No 4, 2010 Vol 21 No 4, 2010 Vol 21 No 3, 2010 Vol 21 No 2, 2010 Vol 21 No 2, 2010 Vol 21 No 1, 2010 Vol 21 No 1, 2010 Vol 20 No 4, 2009 Vol 20 No 4, 2009 Vol 20 No 3, 2009 Vol 20 No 3, 2009 Vol 20 No 2, 2009 Vol 20 No 1, 2009 Vol 20 No 1, 2009 Vol 19 No 4, 2008 Vol 19 No 3, 2008 Vol 19 No 3, 2008 Vol 19 No 2, 2008 Vol 19 No 1, 2008 Vol 19 No 1, 2008 Vol 18 No 4, 2007 Vol 18 No 3, 2007 Vol 18 No 3, 2007 Vol 18 No 2, 2007 Vol 18 No 1, 2007 Vol 17 No 4, 2006 Vol 17 No 3, 2006 Vol 17 No 3, 2006 Vol 17 No 2, 2006 Vol 17 No 2, 2006 Vol 17 No 1, 2006 Vol 17 No 1, 2006 Vol 16 No 4, 2005 Vol 16 No 4, 2005 Vol 16 No 3, 2005 Vol 16 No 2, 2005 Vol 16 No 2, 2005 Vol 16 No 1, 2005 Vol 16 No 1, 2005 Vol 15 No 4, 2004 Vol 15 No 4, 2004 Vol 15 No 3, 2004 Vol 15 No 2, 2004 Vol 15 No 2, 2004 Vol 15 No 1, 2004 Vol 15 No 1, 2004 Vol 14 No 4, 2003 Vol 14 No 3, 2003 Vol 14 No 2, 2003 Vol 14 No 1, 2003 Vol 14 No 1, 2003 Vol 13 No 4, 2002 Vol 13 No 4, 2002 Vol 13 No 3, 2002 Vol 13 No 3, 2002 Vol 13 No 2, 2002 Vol 13 No 2, 2002 Vol 13 No 1, 2002 Vol 12 No 4, 2001 Vol 12 No 4, 2001 Vol 12 No 3, 2001 Vol 12 No 2, 2001 Vol 12 No 2, 2001 Vol 12 No 1, 2001 Vol 12 No 1, 2001 More Issue